FAKTOR OPTIONSSCHEIN - VALNEVA SE Share Price

Certificat

DE000UK2P8K4

Market Closed - Deutsche Boerse AG 16:18:36 14/06/2024 BST
0.001 EUR 0.00% Intraday chart for FAKTOR OPTIONSSCHEIN - VALNEVA SE
Date Price Change
14/06/24 0.001 0.00%
13/06/24 0.001 0.00%
12/06/24 0.001 0.00%
11/06/24 0.001 0.00%
10/06/24 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 04:18 pm

More quotes

Static data

Product typeWarrant Esotici e Strutturati
Buy / SellCALL
Underlying VALNEVA
Issuer UBS
WKN UK2P8K
ISINDE000UK2P8K4
Date issued 12/05/2022
Strike 2.858
Maturity Unlimited
Parity 29850.75 : 1
Emission price 4.72
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.13
Lowest since issue 0.001

Company Profile

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.
Sector
-
More about the company

Ratings for Valneva

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Valneva

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.28 EUR
Average target price
8.967 EUR
Spread / Average Target
+173.37%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW